The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Novel treatment strategies for Richter’s transformation
Jacqueline Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, addresses Richter’s transformation, an aggressive form of chronic lymphocytic leukemia (CLL), as a current area of unmet medical need. Current treatments are inadequate in treating Richter’s transformation and various clinical trials are underway to improve patient outcomes. Novel therapies and regimens such as venetoclax with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), and pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, represent promising treatments for patients with Richter’s transformation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
